Michael "The Situation" Sorrentino Partners With Community Ambassadors to Show the Reality of Opioid Prescription Painkiller

Michael "The Situation" Sorrentino Partners With Community Ambassadors to Show
the Reality of Opioid Prescription Painkiller Addiction and Motivate Americans
                   Battling the Disease to "Reset Reality"

New Public Health Initiative Helps Reveal the Real Situation About Growing
National Epidemic

PR Newswire

RICHMOND, Va., Sept. 10, 2013

RICHMOND, Va., Sept. 10, 2013 /PRNewswire/ -- Michael "The Situation"
Sorrentino today helped launch a new public health initiative titled "Reset
Reality" designed to increase knowledge and understanding of the prevalence,
science and treatment of opioid prescription painkiller addiction – a
condition he personally struggled with until finally seeking help in 2012.
Working in partnership with Reckitt Benckiser Pharmaceuticals Inc. and
community ambassadors from across the country who are also successfully
managing the disease, the group hopes to get the word out  that people don't
have to face the fight alone and can help to reset their situation by working
with a doctor to manage prescription painkiller addiction. Together, they
hope to offer inspiration by sharing their stories of recovery publically,
along with much needed education and information that can be found on the new
resource hub, ResetReality.com.

To view the multimedia content associated with this release, please
click:http://www.multivu.com/players/English/62903-reckitt-benckiser-reset-reality

(Photo:http://photos.prnewswire.com/prnh/20130910/MM75756)

America is facing a growing epidemic: prescription painkiller addiction is an
equal opportunity disease, affecting individuals of all ages, genders, races
and socioeconomic status. Each year for the last 11 years, the number of
people battling this addiction has increased. Today, prescription painkiller
addiction – also known as opioid dependence – affects millions of Americans.
Sadly, it is often a common gateway to heroin and other drug addictions.
While opioid prescription painkillers can be effective medicines, some people
develop a dependence as an unexpected consequence of proper pain treatment.
Over time, opioid prescription painkillers can alter the brain's chemistry by
"resetting" the brain so one begins to feel they need opioid prescription
painkillers just to get through the day. People living with prescription
painkiller addiction often feel isolated and fear being judged or relapsing,
causing them to not seek help.

"People think they know me from what they saw on reality TV, but they didn't
see the real
situation with my prescription painkiller addiction. Fortunately, with the
strong support of my family, I was able to get the help I needed and find a
path forward to help maintain my recovery," Michael said. "I've learned a lot
on my recovery journey, both about myself and this particular addiction.
Prescription painkiller addiction needs to be managed like any other medical
condition: with a commitment to lifestyle changes, treatment and surrounding
yourself with a supportive environment. And I want people to know that no
matter what the situation, a healthy and positive recovery can be possible."

Michael has found that a daily medication that he took in rehab and now takes
daily by prescription from his doctor called SUBOXONE® (buprenorphine and
naloxone) Sublingual Film (CIII) along with counseling has worked best for
him. Through the initiative, the public is encouraged to work with a doctor,
like the "Reset Reality" ambassadors did, to determine what treatment program
will work best for them or a loved one.

Community support and understanding is instrumental to help encourage the
untreated to seek help. A recent national survey^*,** revealed both U.S.
adults and primary care doctors harbor a variety of misperceptions and
stereotypes about opioid dependence that may impact the way the disease – and
those living with it – are treated. For example, more than two-thirds (68
percent) of adults and eight-in-ten doctors (80 percent) surveyed say opioid
dependence represents a mental health problem, and nearly half of adults (45
percent) and almost one-third of doctors (30 percent) believe opioid
dependence is more of a psychological problem (e.g., lifestyle choice) rather
than a physical illness (e.g., chronic disease). Yet, two-thirds of adults
(67 percent) and more than one-third of doctors (35 percent) feel like they do
not know much about opioid dependence. And another 11 percent of adults and 3
percent of doctors believe opioid dependence refers to addiction of any kind
of drug. Conducted in March 2013 by Harris Interactive, the survey was
commissioned by Reckitt Benckiser Pharmaceuticals, the sponsors of "Reset
Reality."

"Although often stigmatized as simply bad behavior, prescription painkiller
addiction is a real medical disease. Similar to other lifelong conditions like
diabetes and asthma, prescription painkiller addiction is not presently
considered curable. It can be successfully treated and controlled," said Adam
Rubinstein, M.D., Advocate Condell Medical Center in Libertyville, Ill. and
NorthShore University HealthSystem in Evanston, Ill. "Reset Reality aims to
correct misperceptions about opioid dependence, as well as create urgency and
action among Americans living with the disease to learn about the chronic
nature of the illness, individualized treatment options and quite simply, how
to access help."

ResetReality.com Offers Education, Resources and Ways to Get Involved
In addition to speaking appearances in cities across the country by Michael
and the community ambassadors, the ResetReality.com website is an integral
part of the public awareness effort. The website provides an online
destination for people to learn about treatment and take action to help
themselves or someone else – as well as to lend support to broader community
awareness. Visitors can access information and tools that address opioid
dependence, including a symptom screener and how to find a doctor that is
certified to treat opioid prescription painkiller and heroin addiction.

People will also find the personal stories from the community ambassadors
about their decision to reset their reality and ongoing efforts to manage
their opioid dependence today. To get involved in the initiative, the public
can share their reality of successfully battling addiction or show support for
anyone who is trying to change their addiction situation by providing
inspirational words, downloading the campaign badge from the website or using
#ResetReality on Facebook or Twitter.

About Opioid Dependence
Often stigmatized as bad behavior, poor judgment and a moral failing on the
part of the patient, opioid dependence – also known as prescription painkiller
or heroin addiction – is a chronic disease caused in part by pervasive changes
in the brain's chemistry that can result from regular use of opioids, such as
oxycodone, morphine and heroin.^1,2,3 These long-lasting changes can interfere
with normal brain functioning, fooling the brain into thinking the opioid is
necessary for survival and resulting in drug-seeking behavior and
dependence.^1,2,3 Similar to other chronic diseases, such as diabetes and
hypertension, opioid dependence requires continued medical care and monitoring
in order to manage it successfully and can be fatal if left untreated.^1,2,3

Opioid dependence has grown to epidemic proportions – affecting men and women
of all ages, races, ethnic groups and educational levels – and currently
represents a national health crisis.^4 As of 2011, approximately 1.8 million
people were living with pain reliever dependence or abuse,^5 but only 40
percent of these individuals were receiving proper treatment for the
disease.^6

About SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII)
SUBOXONE Film, approved by the U.S. Food and Drug Administration (FDA) in
2010, is a trusted and proven treatment option for opioid dependence that
allows patients to be discreetly treated in the privacy of a physician's
office. Because SUBOXONE Film is approved for at-home use, individuals living
with opioid dependence can continue their daily lives while under a
physician's care similar to other chronic diseases, such as diabetes, asthma
or hypertension.

SUBOXONE Film combines buprenorphine and naloxone in a 4:1 ratio and is
available in 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg and 12 mg/3 mg dosage
formulations. Buprenorphine is a partial opioid agonist that strongly binds to
the opioid receptors in the brain and dose-dependently blocks other opioids
from attaching. In doing so, buprenorphine helps reduce opioid use and may
increase treatment retention by helping to manage withdrawal symptoms and
reducing cravings. SUBOXONE Film also includes naloxone, an opioid agonist,
that can cause opioid withdrawal when injected by a person dependent on full
agonist opioids and is intended to help minimize its attractiveness for
deliberate misuse. When SUBOXONE Film is taken as prescribed (i.e. dissolved
under the tongue) the naloxone has no effect.

It is estimated that more than four million Americans living with opioid
dependence have been treated with the active ingredients contained in SUBOXONE
Film since the combination was first approved in tablet formulation by the FDA
in 2003.

About Reckitt Benckiser Pharmaceuticals Inc.
Reckitt Benckiser Pharmaceuticals Inc. is a specialty pharmaceutical company
with a decade of heritage in serving the opioid dependence community.
Committed to expanding education and access to medical therapies, the company
innovates, manufactures and markets medications that, in conjunction with
counseling and psychosocial support, treat opioid dependence. Reckitt
Benckiser Pharmaceuticals Inc. continues to invest resources in raising
awareness of opioid dependence within the community, whilst also sponsoring
training programs for doctors to become certified to treat opioid addicted
patients. The company aims to help patients, while also protecting communities
from the financial and societal burdens of addiction through
mediation-assisted treatment, enabling opioid dependence to be managed within
mainstream medical practice. Reckitt Benckiser Pharmaceuticals Inc. is a
wholly owned subsidiary of Reckitt Benckiser Group plc, a global company
publicly traded on the UK stock exchange.

Indication
SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) is a
prescription medicine used for maintenance treatment of opioid dependence as
part of a complete treatment plan to include counseling and behavioral
therapy.

Important Safety Information
Do not take SUBOXONE® (buprenorphine and naloxone) Sublingual Film if you are
allergic to buprenorphine or naloxone as serious negative effects, including
anaphylactic shock, have been reported.

SUBOXONE Sublingual Film can be abused in a manner similar to other opioids,
legal or illicit.

Important Safety Information Continued
SUBOXONE (buprenorphine and naloxone) Sublingual Film contains buprenorphine,
an opioid that can cause physical dependence with chronic use. Physical
dependence is not the same as addiction. Your doctor can tell you more about
the difference between physical dependence and drug addiction. Do not stop
taking SUBOXONE Sublingual Film suddenly without talking to your doctor. You
could become sick with uncomfortable withdrawal symptoms because your body has
become used to this medicine.

SUBOXONE Sublingual Film can cause serious life-threatening breathing
problems, overdose and death, particularly when taken by the intravenous (IV)
route in combination with benzodiazepines or other medications that act on the
nervous system (ie, sedatives, tranquilizers, or alcohol). It is extremely
dangerous to take nonprescribed benzodiazepines or other medications that act
on the nervous system while taking SUBOXONE Sublingual Film.

You should not drink alcohol while taking SUBOXONE, as this can lead to loss
of consciousness or even death.

Death has been reported in those who are not opioid dependent.

Your doctor may monitor liver function before and during treatment.

Keep SUBOXONE Sublingual Film out of the sight and reach of children.
Accidental or deliberate ingestion of SUBOXONE Sublingual Film by a child can
cause severe breathing problems and death.

Do not take SUBOXONE Sublingual Film before the effects of other opioids (eg,
heroin, hydrocodone, methadone, morphine, oxycodone) have subsided as you may
experience withdrawal symptoms.

Injecting SUBOXONE may cause serious withdrawal symptoms such as pain, cramps,
vomiting, diarrhea, anxiety, sleep problems, and cravings.

Before taking SUBOXONE, tell your doctor if you are pregnant or plan to become
pregnant. If you become pregnant while taking SUBOXONE, alert your doctor
immediately as there may be significant risks to you and your baby; your baby
may have symptoms of withdrawal at birth. If you are pregnant or become
pregnant while taking SUBOXONE, you should report it using the contact
information provided below.*

Before taking SUBOXONE, talk to your doctor if you are breast-feeding or plan
to breast-feed. SUBOXONE can pass into your milk and may harm the baby. Talk
to your doctor about the best way to feed your baby if you take SUBOXONE.
Breast-feeding is not recommended while taking SUBOXONE.

Do not drive, operate heavy machinery, or perform any other dangerous
activities until you know how SUBOXONE affects you. Buprenorphine in SUBOXONE
can cause drowsiness and slow reaction times during dose-adjustment periods.

Common side effects of SUBOXONE Sublingual Film include nausea, vomiting, drug
withdrawal syndrome, headache, sweating, numb mouth, constipation, painful
tongue, redness of the mouth, intoxication (feeling lightheaded or drunk),
disturbance in attention, irregular heartbeat, decrease in sleep, blurred
vision, back pain, fainting, dizziness, and sleepiness.

This is not a complete list of potential adverse events associated with
SUBOXONE Sublingual Film. Please see full Product Information for a complete
list.

Important Safety Information Continued
*To report negative side effects associated with taking SUBOXONE
(buprenorphine and naloxone) Sublingual Film, please call 1-877-782-6966. You
are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full US Product Information and Medication Guide for SUBOXONE
Sublingual Film.

For more information about SUBOXONE® (buprenorphine and naloxone) Sublingual
Tablets (CIII), please see full US Product Information and Medication Guide.

References
1. Cami J, Farre M. (2003). Mechanisms of disease: drug addiction. N Engl J
   Med, 349:975-986
2. Leshner AI. (1997). Addiction is a brain disease, and it matters. Science,
   278:45-47
   World Health Organization. (2004). United Nations Office on Drugs and Crime,
   Joint United Nations Programme on HIV/AIDS. Position paper. Substitution
3. maintenance therapy in the management of opioid dependence and HIV/AIDS
   prevention. Accessed July 23, 2013 at
   http://www.who.int/substance_abuse/publications/en/PositionPaper_English.pdf
   Substance Abuse and Mental Health Services Administration. (September 2010).
   Treatment Episode Data Set: Characteristics of Substance Abuse Treatment
4. Admissions Reporting Primary Abuse of Prescription Pain Relievers: 1998 and
   2008. Accessed July 23, 2013 at
   http://www.oas.samhsa.gov/2k10/230b/230bPainRelvr2k10Web.pdf
5. Data on file. Reckitt Benckiser Pharmaceuticals, Inc.
   Substance Abuse and Mental Health Services Administration, Results from the
6. 2010 National Survey on Drug Use and Health: Summary of National Findings,
   NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD:
   Substance Abuse and Mental Health Services Administration, 2011.
*  Primary care, internal medicine and family medicine physicians who were not
   Drug Addiction Treatment Act (DATA) 2000 certified.
   More than 1,000 adults ages 26-49 ("adults") were surveyed between January
** 2-7, 2013 and 200 non-DATA 2000 certified primary care doctors ("doctors")
   were surveyed between March 13-22, 2013.

SOURCE Reckitt Benckiser Pharmaceuticals

Contact: Alana Rockland, Biosector 2, 1-212-845-5651,
ARockland@Biosector2.com; Alice Sofield, Biosector 2, 1-703-861-5654,
ASofield@Biosector2.com